Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS - Summary - MDSpire
Advertisement
Evaluating the Effectiveness of Rituximab in Children with Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome Associated with MCD or FSGS
To evaluate the efficacy of rituximab in children with steroid-dependent or frequently relapsing nephrotic syndrome associated with minimal change disease (MCD) or focal segmental glomerulosclerosis (FSGS), focusing on primary outcome measures such as remission rates and relapse frequency.
Key Findings:
All patients achieved clinical remission, with 90.5% attaining complete remission. Relapse rates decreased to 35.7% within 1 year after the first rituximab treatment, indicating significant improvement.
No significant difference in relapse rates was observed between patients receiving different doses of rituximab.
Higher relapse-free survival was noted in the FSGS group compared to MCD controls, suggesting a potential difference in treatment response.
Interpretation:
Rituximab is effective for treating SDNS/FRNS in children, regardless of whether the underlying condition is MCD or FSGS, supporting its repeated use, but findings should be interpreted with caution due to the small sample size.
Limitations:
Small sample size, particularly in the FSGS subgroup, and potential biases inherent in retrospective design.
Conclusion:
Rituximab shows promise in managing SDNS/FRNS in children, but findings require validation through larger, multicenter studies to confirm efficacy and safety.
